(Q37401531)

20 August 2017

Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis (English)

1 reference

20 August 2017

1 reference

1 reference

13

O Dahl

1 reference

20 August 2017

12

L A Akslen

1 reference

20 August 2017

1

Ø Fluge

1 reference

Norwegian Gastrointestinal Cancer Group

20 August 2017

14

object named as

Norwegian Gastrointestinal Cancer Group

1 reference

20 August 2017

K Gravdal

2

1 reference

20 August 2017

E Carlsen

3

1 reference

20 August 2017

B Vonen

4

1 reference

20 August 2017

K Kjellevold

5

1 reference

20 August 2017

S Refsum

6

1 reference

20 August 2017

R Lilleng

7

1 reference

20 August 2017

T J Eide

8

1 reference

20 August 2017

T B Halvorsen

9

1 reference

20 August 2017

K M Tveit

10

1 reference

20 August 2017

A P Otte

11

1 reference

20 August 2017

language of work or name

English

0 references

publication date

22 September 2009

1 reference

British Journal of Cancer

20 August 2017

1 reference

20 August 2017

101

1 reference

20 August 2017

8

1 reference

20 August 2017

1282-1289

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605333

20 August 2017

0 references

cites work

Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Ki67 protein: the immaculate deception?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

EZH2 promotes proliferation and invasiveness of prostate cancer cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Activated p53 suppresses the histone methyltransferase EZH2 gene

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768450

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

2 September 2018

1 reference

12 December 2020

Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01

1 reference

12 December 2020

Adjuvant therapy for stage II and III colorectal cancer

1 reference

12 December 2020

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

1 reference

12 December 2020

Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605333

1 reference

release_45sjxtvgrzbf5pjgsfqx6yz36a

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/45sjxtvgrzbf5pjgsfqx6yz36a

24 November 2022

mapped directly with Wikidata item

1 reference

20 August 2017

PubMed publication ID

19773751

1 reference